Stockscreener 앱 받기
149.16
0.51%
0.76
시간 외 거래:
149.04
-0.12
-0.08%
Novartis Ag Adr 주식(NVS)의 최신 뉴스
IEFA: Why This Fund Is One of the Best International ETFs - The Motley Fool
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG stock (CH0012005267): Pluvicto data keep focus on Swiss blue-chip pharma - AD HOC NEWS
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG (ADR) stock (CH0012005267): steady trading ahead of next catalysts - AD HOC NEWS
Novartis AG stock (CH0012005267): shares little changed as investors digest Swiss pharma group’s s - AD HOC NEWS
Novartis AG stock (CH0012005267): focus on Sandoz spin-off and pipeline momentum - AD HOC NEWS
NVS Technical Analysis | Trend, Signals & Chart Patterns | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG stock (CH0012005267): eyeing Sandoz spin-off and new drug approvals - AD HOC NEWS
Novartis AG stock (CH0012005267): new MS drug filing and Q1 momentum attract attention - AD HOC NEWS
Novartis AG stock (CH0012005267): Q1 update, Sandoz deconsolidation and pharma focus draw investor a - AD HOC NEWS
Novartis AG stock (CH0012005267): oncology focus, new drug readout and solid 2025 guidance in view - AD HOC NEWS
NVS Stock Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis stock (CH0012005267): FDA progress and market focus - AD HOC NEWS
Novartis AG stock (CH0012005267): dividend profile and pipeline focus move into the spotlight - AD HOC NEWS
Novartis AG stock (CH0012005267): US expansion push with new Texas radioligand site - AD HOC NEWS
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis AG stock (CH0012005267): Recent 1.93% gain on SIX Swiss Exchange - AD HOC NEWS
Novartis AG stock (CH0012005267): NewEdge Wealth boosts stake amid mixed analyst views - AD HOC NEWS
NVSNovartis AG ADR Stock Price and Quote - Finviz
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities - ChartMill
Trump's Drug Pricing Deals Could Lead To $529 Billion Savings For The Economy Over The Decade: Report - Sahm
Sandoz, Novartis Must Face Generics Claims From GM, Others - Law360
PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers - Sahm
Novartis AG Stock (CH0012005267): Q1 Revenue Miss Triggers Decline - AD HOC NEWS
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility - ChartMill
Novartis CEO Flags Risks From Trump's MFN Drug Policy As Q1 Earnings Miss Estimates - Sahm
Earnings call transcript: Novartis Q1 2026 earnings miss forecasts, stock dips - Investing.com
Earnings call transcript: Novartis Q1 2026 earnings miss forecasts, stock dips By Investing.com - Investing.com Canada
Novartis (NYSE: NVS) Q1 2026 earnings dip as key drugs surge, Avidity deal closes - Stock Titan
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed - ChartMill
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria - ChartMill
Novartis AG (NVS) Stock Price, Trades & News - GuruFocus
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA) - ChartMill
Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - GlobeNewswire Inc.
2.28%
1.81%
자본화:
|
볼륨(24시간):